Cytotoxic T cells (CTLs) specific for the hematopoietic system specific minor histocompatibility antigen (mHag) HA-1 effectively lyse leukemic cells and their clonogenic precursors without affecting non-hematopoietic cells. Thus, adoptive transfer of in vitro generated HA-1 specific CTLs in HA-1 positive patients with relapsed leukemia may be curative with a low risk of graft versus host disease. In vitro generation of HA-1 specific CTLs is possible using dendritic cells (DCs) pulsed with synthetic HA-1 peptide but is not always successful under GMP conditions. Therefore we investigated whether HA-1 specific CTLs can be effectively generated using DCs retrovirally transduced to express the HA-1 CTL epitope. The cDNA coding for the HA-1 CTL epitope was cloned into the retroviral construct LZRS and transduced into CD34+ DC progenitors with 10-40 % efficiency. CD34+ cells showed stable and functional expression of the transgene, differentiated normally into immature DCs and retained this immature phenotype during the CTL cultures. Retrovirally transduced DCs, independent of the transduction efficiency, induced HA-1 specific CTLs in four out of six HA-1 negative healthy stem cell donors. After one or two rounds of restimulation, the CTL cultures contained 6-9 % T cells brightly staining with HLA-A2/HA-1 peptide tetramer and showed significant lysis of HA-1 positive target cells. The CTL induction by peptide pulsed DCs executed in parallel was less effective and required three to five rounds of restimulation. Our results show that retrovirally transduced DCs efficiently induce HA-1 specific CTLs through sustained antigen presentation to unprimed T cell precursors.
T. Mutis, K. Ghoreschi, E. Schrama, J. Kamp, M. Heemskerk, J.H.F. Falkenburg, E. Goulmy (Leiden, NL; Munich, D) Cytotoxic T cells (CTLs) specific for the hematopoietic system specific minor histocompatibility antigen (mHag) HA-1 effectively lyse leukemic cells and their clonogenic precursors without affecting non-hematopoietic cells. Thus, adoptive transfer of in vitro generated HA-1 specific CTLs in HA-1 positive patients with relapsed leukemia may be curative with a low risk of graft versus host disease. In vitro generation of HA-1 specific CTLs is possible using dendritic cells (DCs) pulsed with synthetic HA-1 peptide but is not always successful under GMP conditions. Therefore we investigated whether HA-1 specific CTLs can be effectively generated using DCs retrovirally transduced to express the HA-1 CTL epitope. The cDNA coding for the HA-1 CTL epitope was cloned into the retroviral construct LZRS and transduced into CD34+ DC progenitors with 10-40 % efficiency. CD34+ cells showed stable and functional expression of the transgene, differentiated normally into immature DCs and retained this immature phenotype during the CTL cultures. Retrovirally transduced DCs, independent of the transduction efficiency, induced HA-1 specific CTLs in four out of six HA-1 negative healthy stem cell donors. After one or two rounds of restimulation, the CTL cultures contained 6-9 % T cells brightly staining with HLA-A2/HA-1 peptide tetramer and showed significant lysis of HA-1 positive target cells. The CTL induction by peptide pulsed DCs executed in parallel was less effective and required three to five rounds of restimulation. Our results show that retrovirally transduced DCs efficiently induce HA-1 specific CTLs through sustained antigen presentation to unprimed T cell precursors.
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Minor histocompatibility antigens on canine hematopoietic precursor cells
Adoptive immunotherapy with cytotoxic T lymphocytes (CTL) immunized against minor histocompatibility antigens (mHA) offers a promising way to treat leukemia. Here we report the in vitro and in vivo immunization of CTLs against mHA in DLA-identical canine littermates. First, we established optimal culture conditions for canine dendritic cells (DC). Canine bone marrow cells were depleted of T-cells, B-cells, granulocytes and monocytes. DC were generated from these cells in the presence of 800 U/ml GM-CSF for 10 to 12 days. They were characterized by their morphology, a high expression of MHC class II and CD1a, a high stimulatory activity in the allogeneic mixed lymphocyte reaction (MLR) and high stimulatory activity of autologous T cells after pulsing with KLH. These DC were used for the generation of CTLs using co-culture with donor-derived T cells or for in vivo immunization of the donor. The capacity of the CTLs to suppress the growth of HPC was shown in a Delta-Assay, performed in analogy of the delta culture in the mouse (Muench MO and Moore MA, 1992) using canine lineage-negative bone marrow as target cells. The target cells were plated in a 96-well plate at decreasing cell numbers ranging from 16.000 to 125 cells per well. The growth of HPC was stimulated by the addition of 100 ng/ml SCF, 800 U/ml GM-CSF, 2 U/ml Epo, 100 ng/ml IL-3 and 3% allogeneic MLR supernatant. At the start of the Delta Assay irradiated CTLs were added to the wells in a fixed number of 10.000 cells, resulting in a range of effector to target cell ratios from 0.6:1 to 80:1. After 4 days the 3H-thymidine uptake of the target cells was measured and compared to the control. The results showed a specific inhibition of HPC-growth in 63% (5/8) analyzed canine littermate combinations. Segregation analysis showed one way reactivity in two cases. One setting between two male littermates proved the involvement of autosomally-encoded mHA. The other situation is showing a one-way reaction of femalederived CTLs against male HPC, possibly indicating a Y-chromosome coded mHA. Further evidence of Y-chromosome encoded mHA is provided by the strength of the suppression which is similar to the human situation. We have shown the in vitro generation of canine DC, the in vitro and in vivo immunization of CTLs against mHA in DLA-identical canine littermates and the specific cytotoxic activity of these CTLs against HPC.
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Human CD8+ T-cell lines specific for BCR-ABL peptides located outside the junction can recognize fresh leukemic cells A. Michallet, G. Gallot, C. Boix, B. Varet, J. Guillet, H. Vié , A. Buzyn (Paris, Nantes, F) we have previously shown with an ELISpot IFN-g assay that CML patients havec circulating CD8+ precursors specific for BCR-ABL peptides located outside the junction, and that the presence of these memory cells is corelated to the stability of the peptide-HLA class I complexes. in order to determine the clinical relevance of these findings, we looked for the capacity of these peptides to elicit CTL lines from CML patients, able to recognize fresh leukemic cells. For this, peptides were chosen for their capacity to give stable complexes to HLA class I molecules ( half life Ͼ 24 hours) and for the presence of specific CD8+ memory T cells in CML patients. Because the frequency of CD8+ specific precursors in leukemic patients is usually low, we used a new procedure for enrichment and selection of ex vivo BCR-ABL specific CD8+ T cells. After selection, these cells were amplified using a classic method of culture with IL-2, specific peptides and allogeneic feeder cells. The specificity of the CD8+ T celle lines was assessed by using an ELIspot IFN-g assay. Results showed the narrow specificity the CD8+ T cell lines obtained from 4 CML patients, for the stimulating peptide and not for other BCR-ABL or viral control peptides,confirming the interest of that selection procedure isolate peptide-specific T cells. A CD8+ T cell line specific for a HLA-A2 binding BCR peptide, close to the b3a2 junction, was shown to recognize HLA-A2 CML cells but not non-A2 CML cells nor HLA-A2 AML cells. These results suggest that BCR-ABL peptide located outside the junction are presented by CML leukemic cells and induce a natural immune response in patients, supporting the development of vaccination strategies with BCR-ABL peptides in CML patients.
P375
Molecular identification of leukemia-associated minor histocompatibility antigens by cDNA expression cloning B. de Rijke, A. Zoetbrood, H. Fredrix, E. Warren, T. de Witte, E. van de Wiel-van Kemenade, H. Dolstra (Nijmegen, NL; Seattle, USA)
HLA-identical allogeneic stem cell transplantation (SCT) is the treatment of choice for patients with leukemia. The therapeutic effect is for a major part attributed to an immune-mediated anti-tumor reactivity, which is called the Graft-versus-Leukemia (GVL) reactivity. It is now clear that donor cytotoxic T lymphocytes (CTL) play an important role in this GVL reactivity by specifically eliminating residual leukemic cells. Unfortunately, in many SCT recipients induction of Graft-versus-Host-disease (GVHD) results in high morbidity and mortality. GVL and GVHD are both initiated by incompatibilities between donor and recipient for minor histocompatibility antigens (mHag). To enhance the beneficial GVL reactivity by vaccination without augmenting GVHD, it is necessary to identify CTL-defined mHag, which are exclusively expressed by hematopoietic or leukemic cells. The expression cloning strategy, which has proven to be very successful in identifying a number of melanoma derived antigens, is now exploited by us to discover leukemia-associated mHag. By this approach, we have identified the first B-lineage ALL-specific mHag, called HB-1 (Dolstra et al, J. Exp. Med., 1999) . Recently, we have determined the expression frequencies and tissue distribution of two other novel tissue-restricted mHag recognized by cytotoxic T cells. HLA-B*702 restricted CTL recognize EBV-LCL, CD40L stimulated B cells and PHA stimulated T blasts, but not dendritic cells. In contrast, expression of the HLA-B* 4403 restricted mHag is restricted to EBV-LCL and CD40L stimulated B cells. Molecular identification of these CTL-defined mHag by cDNA expression cloning is highly dependent on the growth and sensitivity of the CTL. To increase the chance of success and to be less dependent of the CTL condition we have further optimized the cDNA transfection procedure. Using this improved screening procedure we currently attempt to identify these novel leukemia-associated mHag. Recently, we defined the molecular nature of the polymorphic HB-1 antigen which is exclusively expressed in B-lineage acute lymphoblastic leukemia (ALL) and EBV-transformed B cells. The gene has two alleles, HB-1H and HB-1Y, which code for proteins differing by a single amino acid. We have previously found that the HB-1H-derived peptide EEKRGSLHVW induced in vivo allogeneic HLA-B44-restricted cytotoxic T lymphocytes (CTL) specifically killing B-lineage ALL cells of the HLA-identical bone marrow recipient. These findings suggest strongly that the HB-1 protein constitute a very useful target for immunotherapeutic approaches. In the present study, we demonstrate that from six out of eight healthy donors HB-1H.B44 peptide-specific CTL lines could be generated by stimulating CD8+ T cells repeatedly with peptide-loaded mature dendritic cells. These in vitro-induced CTL lines significantly lysed peptide-pulsed autologous PHA-stimulated T cells, autologous HB-1H-expressing EBV-transformed B cells and Raji tumor cells transfected with HLA-B44 together with the HB-1H allele. Characterization of individual anti-HB-1 CTL clones revealed that despite they are able to recognize the naturally processed epitope they are of low-avidity quality compared to the in vivo-induced allogeneic CTL clone. Interestingly, we found that the HB-1Y-derived peptide EEKRGSLYVW can also be properly processed by the proteasome and presented by HLA-B44 molecules. Furthermore, after stimulation of CD8+ T cells with peptide-loaded autologous dendritic cells we obtained HB-1Y.B44-specific CTL recognizing Raji tumor cells cotransfected with HLA-B44 and the HB-1Y allele. The existence of autologous T cell precursors capable of recognizing HB-1-derived peptides further illustrates the use of the HB-1 antigen as a vaccine to induce specific anti-tumor CTL reactivity in B-lineage ALL patients.
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Interindividual conservation of T-cell receptor beta-chain variable region (tcrbv) repertoire by in vitro generated minor histocompatibility antigen ha-1-specific Cytotoxic T-cells (CTL's) R.M. Verdijk, T. Mutis, J. Kamp, E. Schrama, A. Brand, M. Wilke, E. Goulmy (Leiden, NL)
The hematopoietic system specific minor Histocompatibility antigen HA-1 induces HLA-A2 restricted CTL's after bone marrow transplantation between HA-1 disparate individuals. We have previously shown that all HA-1 specific CTL clones isolated from 3 different patients after bone marrow transplantation exclusively use TCRBV6.9 for their TCR, indicating the selection of highly similar TCRBV regions by the HA-1/HLA-A2 complex. HA-1 specific CTL lines can be generated in vitro from healthy individuals using HA-1 peptide pulsed or HA-1 gene transduced DC's. We now questioned whether similar TCRBV regions are used by in vitro generated HA-1 specific CTL's. TCRBV usage of HA-1 specific polyclonal CTL's generated from 7 different individuals were analyzed by spectratyping. RT-PCR for specific TCRBV was performed on 8 in vitro generated HA-1 specific CTL clones from two different individuals. Strongly lytic HA-1 specific CTL lines contained high percentages of HA-1-tetramer positive cells and showed narrowing of CDR3 region size usage for TCRBV6. Narrowing for other TCRBV families occurred at random. No TCRBV6 CDR3 region narrowing was detectable in CTL lines with HA-1 tetramer staining below 10%. However after FACS sorting of HA-1 tetramer positive cells narrowing of CDR3 region size usage for TCRBV6 could be demonstrated. All tested HA-1 specific CTL clones expressed TCRBV6. So far sequencing of three CTL clones confirmed the TCRBV6.9 usage. These results indicate that similar to in vivo induced HA-1 specific CTL's, in vitro generated HA-1 specific CTL's also show highly restricted TCRBV usage. The minor histocompatibility antigen (mHag) HA-1 is a haematopoietic system specific polymorphic protein encoded by a locus with two alleles that differ by only one amino acid i.e. a histidine (H) is substituted by an arginine (R). The HA-1(H) allele
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